Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
6.5
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales7,492million yenYear on year +6.5%Progress 22.4%
Operating profit2,737million yenYear on year -2.3%Progress 22.3%
Ordinary income2,907million yenYear on year +2.2%Progress 23.3%
Net income attributable to owners of the parent2,075million yenYear on year +2.5%Progress 23.6%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥84.29
Financial position at period-end
Total assets60,605million yen
of which net assets 56,087 million yenEquity ratio 92.5%vs. prior year-end +5.4pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenuePharmaceuticals business 7,057 million yen (YoY +18.2%), Equipment business 435 million yen (YoY -59.2%)
Segment profitPharmaceuticals business 2,939 million yen (YoY +3.4%), Equipment business 57 million yen (YoY -72.1%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales33,400 million yen (YoY +12.6%)
Operating profit12,300 million yen (YoY +1.2%)
Ordinary income12,500 million yen (YoY +0.4%)
Net income8,800 million yen (YoY -3.0%)
Annual Dividend Forecast95 yen → 180 yen
Factors Behind Changes in Business Performance
Shipments of various products increased, driven by active investment in server-related fields, including generative AI, and steady performance in high-performance electronic devices. While net sales and segment profit in the Chemicals business increased, net sales and segment profit in the Equipment business declined substantially, despite orders progressing as scheduled.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name None / Excluded Number of companies 0 / Company name None
Impairment lossNot applicable (no significant impairment loss on fixed assets)
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets 2 million yen / Extraordinary loss Loss on Disposal of Fixed Assets 0 million yen
Depreciation and amortization572 million yen
Orders received and order backlogOrders received 1,135 million yen (YoY +212.0%) / Order backlog 1,114 million yen (YoY +80.3%)
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End26,219,049 Shares
Treasury Shares at Period-End1,599,326 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | 7,492 million yen (YoY +6.5%) |
| Operating profit | 2,737 million yen (YoY -2.3%) |
| Ordinary income | 2,907 million yen (YoY +2.2%) |
| Profit attributable to owners of the parent | 2,075 million yen (YoY +2.5%) |
| Net income per share | ¥84.29 |
| Equity ratio | End of the current fiscal period 92.5 / End of previous period 87.1 |
| Total assets | 60,605 million yen |
| Net assets | 56,087 million yen |
| Full-year earnings forecast | Net Sales 33,400 million yen (YoY +12.6%) / Operating profit 12,300 million yen (YoY +1.2%) / Ordinary income 12,500 million yen (YoY +0.4%) / Net income 8,800 million yen (YoY -3.0%) |
| Annual Dividend Forecast | 95 yen → 180 yen |
| Segment revenue | Pharmaceuticals business 7,057 million yen (YoY +18.2%), Equipment business 435 million yen (YoY -59.2%) |
| Segment profit | Pharmaceuticals business 2,939 million yen (YoY +3.4%), Equipment business 57 million yen (YoY -72.1%) |
| Orders received and order backlog | Orders received 1,135 million yen (YoY +212.0%) / Order backlog 1,114 million yen (YoY +80.3%) |
| Depreciation and amortization | 572 million yen |
| Impairment loss | Not applicable (no significant impairment loss on fixed assets) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 2 million yen / Extraordinary loss Loss on Disposal of Fixed Assets 0 million yen |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name None / Excluded Number of companies 0 / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 26,219,049 Shares |
| Treasury Shares at Period-End | 1,599,326 Shares |
| Factors Behind Changes in Business Performance | Shipments of various products increased, driven by active investment in server-related fields, including generative AI, and steady performance in high-performance electronic devices. While net sales and segment profit in the Chemicals business increased, net sales and segment profit in the Equipment business declined substantially, despite orders progressing as scheduled. |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Shipments of various products increased, driven by investment in server-related fields, including generative AI, and steady performance in high-performance electronic devices. The Chemicals business reported higher sales and profit, while the Equipment business saw a substantial decline in net sales and segment profit, despite orders progressing as scheduled.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.